Navigation Links
Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
Date:1/3/2008

CAMBRIDGE, Mass., Jan. 3 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Company's Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career.

"It is a great pleasure to welcome Boyd Clarke as Chairman of our Board of Directors," said Julie A. Olson, PhD, President and Chief Executive Officer at Mersana. "Boyd brings diverse management experience and commercial expertise in areas important to Mersana at our stage of development. His skills complement those of our existing team very well, and we anticipate his strategic leadership will be of considerable value as we advance our pipeline."

Over the past 11 years Mr. Clarke has held the role of Chairman and Chief Executive Officer at several publicly-held biotechnology companies, most recently Neose Technologies. During his four year tenure at Neose, Mr. Clarke led the company from a platform-based discovery operation to a clinical stage development company with multiple product candidates. As President and CEO of Aviron he oversaw the Biological Licensing Application (BLA) submission for the company's lead product and ultimately secured the sale of the vaccine company to MedImmune. He also served as President and CEO of US Bioscience. Mr. Clarke began his pharmaceutical career at Merck, where he held a series of increasingly responsible positions, including President of Pasteur Merieux MSD and Vice President of Merck Vaccines. He holds a Bachelor of Science degree and a Master of Arts degree from the University of Calgary. Mr. Clarke serves on the Board of Directors of QLT, Inc. and Rib-X, and is a past board member of the Biotechnology Industry Association (BIO).

"Mersana's Fleximer(R) technology has the potential to create safer and more efficacious cancer drugs, and the promise of the technology is now being dem
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Below is,updated text of Shire plc,s conference call notification. ... been updated from an earlier,release. Shire PLC (LSE: ... will announce third quarter 2007 earnings on,Thursday 1 November ... 12:00 GMT / 08:00 ET, Investor meeting and ...
... (Nasdaq: ARNA ) today reported financial results for ... in the third quarter of 2007 were $5.0 million, ... Total revenues in the first,nine months of 2007 were ... months of 2006. Revenues in the first nine months ...
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced that ... on Wednesday, October 24,2007 after the market closes. The ... 5:00 p.m. ET, which will be open to the ... company will review,the financial results and discuss other business ...
Cached Biology Technology:Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast 2
(Date:8/31/2014)... the greatest challenges in modern medicine is developing drugs ... minimal toxicity and side-effects to the patient. Such properties ... drug molecule. Ideally, the drug should have a shape ... that it binds it with high specificity. Publishing in ... synthetic amino acid that can impact the 3D structure ...
(Date:8/31/2014)... malaria diagnosis has changed very little. After taking a blood ... a glass slide, stains it with a special dye, and ... the disease. This approach gives an accurate count of how ... of disease severity but is not ideal because there ... the Singapore-MIT Alliance for Research and Technology (SMART) has now ...
(Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3A new way to diagnose malaria 2A new way to diagnose malaria 3New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... CAMBRIDGE, Mass. (March 16, 2011) Renowned cancer researchers ... Douglas Hanahan, Director of the Swiss Institute for Experimental ... "Hallmarks of Cancer," which has influenced the study of ... a decade. Published in January 2000, their original ...
... Global Change Biology Bioenergy proposes a new method ... in bioenergy systems. CO 2 emissions resulting from ... and environmental impact studies because bioenergy is carbon- and climate- ... combustion are sequestered by growing biomass. Its climate impact has ...
... Mass., March 16, 2011 The nutritional content of ... as owner,s perceptions about them, according to a study ... School of Veterinary Medicine at Tufts University. ... humans and petschange with aging, the Association of American ...
Cached Biology News:Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3Wide variety in nutritional content found in 'senior' dog foods 2Wide variety in nutritional content found in 'senior' dog foods 3
... COOLSCOPE is an integrated digital microscope and ... computer, equipment setup, optical adjustment or software ... innovative technology, COOLSCOPE combines simplicity and advanced ... COOLSCOPE offers simultaneous viewing of a macro ...
... kit provides complete components including positive ... detection of DNA fragmentation in cultured ... of BrdU in the procedure provides ... methods. Results can be analyzed by ...
... Life Science LAS-3000 imaging system combines ... simplified user interface, providing significantly improved ... of modularities. The system is especially ... perfect standard system for Western blotting ...
... Science LAS-3000mini is a compact image ... applications, and the perfect standard system ... LAS-3000 provides significantly improved system sensitivity ... calibration standards validate that Fujis LAS-3000 ...
Biology Products: